Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=19389500&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib Mitsiades CS; Hideshima T; Chauhan D; McMillin DW; Klippel S; Laubach JP; Munshi NC; Anderson KC; Richardson PGSemin Hematol 2009[Apr]; 46 (2): 166-75The successful clinical development of thalidomide, bortezomib, and lenalidomide not only transformed the therapeutic management of multiple myeloma (MM) but also catalyzed a renewed interest in the development of additional classes of novel agents for this disease. This review focuses on a series of new therapeutics that have shown promising preclinical results, as well as encouraging safety profiles and early evidence of anti-MM activity in clinical studies, either alone or in combination with other, conventional or novel, anti-MM treatments. These agents include second-generation proteasome inhibitors and immunomodulatory agents, as well as members of other therapeutic classes, such as histone deacetylase inhibitors (HDAC), heat shock protein 90 (Hsp90) inhibitors, and the alkylphospholipid Akt inhibitor perifosine.|Animals[MESH]|Antineoplastic Agents/*therapeutic use[MESH]|Boronic Acids/therapeutic use[MESH]|Bortezomib[MESH]|Drug Screening Assays, Antitumor[MESH]|Enzyme Inhibitors/*therapeutic use[MESH]|HSP90 Heat-Shock Proteins/antagonists & inhibitors/metabolism[MESH]|Histone Deacetylase Inhibitors[MESH]|Histone Deacetylases/metabolism[MESH]|Humans[MESH]|Immunologic Factors/therapeutic use[MESH]|Multiple Myeloma/*drug therapy/metabolism[MESH]|Phosphorylcholine/analogs & derivatives/therapeutic use[MESH]|Proto-Oncogene Proteins c-akt/antagonists & inhibitors/metabolism[MESH]|Pyrazines/therapeutic use[MESH] |